ENGOT en29 Trofuse-033

About this trial

Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent.

Enometrial Cancer is a type of cancer that starts in the tissues inside the uterus (womb)
pMMR indicates that certain normal proteins are present in the cancer cells
Advanced means the cancer has spread locally or to other parts of the body (metastatic) and cannot be removed with surgery
Recurrent means the cancer came back after surgery

Sacituzumab tirumotecan (also known as sac-TMT) and pembrolizumab are the study medicines. Sac-TMT is an antibody drug conjugate (ADC). An ADC attaches to specific targets on cancer cells and delivers treatment to destroy those cells.

The goal of this study is to learn if people who receive sac-TMT with pembrolizumab live longer and without the cancer getting worse compared to people who receive pembrolizumab alone.

Patient Profile

Women aged 18 or older with advanced or recurrent endometrial cancer — meaning the disease has either spread beyond what can be removed by surgery or has come back after earlier treatment.
Their cancer needs to be proven as “mismatch repair proficient (pMMR)”
They must not have had certain prior treatments (especially certain immunotherapies or targeted drug-conjugates) as defined by the study protocol

Where’s this trial being run?

Cork University Hospital, St James’s Hospital, St Vincents University Hospital, and Mater Misericordiae University Hospital

Can I join this study / trial?

The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.

It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	ENGOT en29 Trofuse-033
Number:	25-17
Full Title:	A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer (TroFuse-033)

Principal Investigator:	Dearbhaile Collins (Cork University Hospital)
Type:	Collaborative
Sponsor:	MSD
Recruitment Started:	Global: June 2025 Ireland: November 2025

Global Recruitment Target:	1123
Ireland Recruitment Target:	34